Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adenosine Injection in Patients Undergoing Coronary Artery Bypass Graft Surgery
IRCT20260104068545N1Phase 3Recruiting
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of adenosine in coronary arteriosclerosis, sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Started May 2026; status: recruiting.
02
Drugs
adenosine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20260104068545N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260104068545N1.